公开(公告)号：WO2010044506A2

公开(公告)日：2010-04-22

申请号：PCT/KR2008/006614

申请日：2008-11-10

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  PARK, Young Woo ,  CHOI, So-Young ,  JANG, Young-Soon ,  PARK, Ji Hyun ,  SONG, Eun-Jung ,  YU, Jung ,  SOHN, Myung-Ho ,  JEON, Jae Won ,  JUNG, Joon-Goo ,  KIM, Sungsub ,  JANG, Myeoung Hee

Inventor： PARK, Young Woo ,  CHOI, So-Young ,  JANG, Young-Soon ,  PARK, Ji Hyun ,  SONG, Eun-Jung ,  YU, Jung ,  SOHN, Myung-Ho ,  JEON, Jae Won ,  JUNG, Joon-Goo ,  KIM, Sungsub ,  JANG, Myeoung Hee

IPC: C07K16/18

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00 ,  C12N9/6424

Abstract: The present invention relates to a transmembrane protease, serine (TMPRSS4) -specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to TMPRSS4. The TMPRSS4- specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.

Abstract translation: 本发明涉及跨膜蛋白酶丝氨酸（TMPRSS4）特异性人抗体，并且更具体地涉及包含互补决定区（CDR）和框架区（FR）的人抗体，所述互补决定区（CDR）和框架区（FR）来源于 与TMPRSS4特异性结合的人抗体。 在本发明的各种癌细胞中表达的TMPRSS4特异性人抗体可用于癌症的诊断，疾病的分类，可视化，治疗和预后评估。

公开(公告)号：WO2010087594A3

公开(公告)日：2010-10-21

申请号：PCT/KR2010000315

申请日：2010-01-18

Applicant: KOREA RES INST OF BIOSCIENCE ,  PARK YOUNG WOO ,  JEON JAE WON ,  JUNG JOON-GOO ,  CHOI HYE IN ,  SOHN MYUNG-HO ,  KIM HO YOUN ,  CHO MI-LA ,  JANG YOUNG-SOON ,  MOON JI-HUN ,  PARK JI HYUN

Inventor： PARK YOUNG WOO ,  JEON JAE WON ,  JUNG JOON-GOO ,  CHOI HYE IN ,  SOHN MYUNG-HO ,  KIM HO YOUN ,  CHO MI-LA ,  JANG YOUNG-SOON ,  MOON JI-HUN ,  PARK JI HYUN

IPC: A61K39/395 ,  A61K31/7105 ,  A61P29/00 ,  A61P37/08 ,  G01N33/53

CPC classification number: A61K31/7105 ,  G01N33/6893 ,  G01N2333/70596

Abstract: The present invention relates to an anti-inflammatory composition using an antibody specifically binding to CD93 or a soluble fragment thereof, a method for diagnosing inflammatory diseases using an aptamer or an antibody specifically binding to CD93 or a soluble fragment thereof, and a kit for diagnosing inflammatory diseases.

Abstract translation: 本发明涉及使用特异性结合CD93的抗体或其可溶性片段的抗炎组合物，使用适体或与CD93特异性结合的抗体或其可溶性片段来诊断炎性疾病的方法，以及诊断用试剂盒 炎性疾病。

公开(公告)号：WO2003048345A1

公开(公告)日：2003-06-12

申请号：PCT/KR2002/002309

申请日：2002-12-07

Applicant: TOOLGEN, INC. ,  KIM, Jin-Soo ,  PARK, Kyung-Soon ,  LEE, Dong-ki ,  SEOL, Wongi ,  LEE, Horim ,  LEE, Seong-il ,  YANG, Hyo-Young ,  LEE, Yangsoon ,  JANG, Young-Soon

Inventor： KIM, Jin-Soo ,  PARK, Kyung-Soon ,  LEE, Dong-ki ,  SEOL, Wongi ,  LEE, Horim ,  LEE, Seong-il ,  YANG, Hyo-Young ,  LEE, Yangsoon ,  JANG, Young-Soon

IPC: C12N5/00

CPC classification number: C12N5/04 ,  C12N5/06 ,  C12N15/1079 ,  C12N2510/00 ,  C12N2510/02

Abstract: In one aspect, a library of nucleic acids that encode different artificial, chimeric proteins is screened to identify a chimeric protein that alters a phenotypic trait of a cell or organism. The chimeric protein can be identified without a priori knowledge of a particular target gene or pathway. Some chimeric proteins include multiple zinc finger domains and can induce, for example, thermotolerance, solvent-tolerance, altered cellular growth, insulin production, differentiation, and drug resistance.

Abstract translation: 在一个方面，筛选编码不同人造嵌合蛋白质的核酸文库，以鉴定改变细胞或生物体的表型性状的嵌合蛋白质。 可以在没有特定靶基因或途径的先验知识的情况下鉴定嵌合蛋白。 一些嵌合蛋白包括多个锌指结构域并且可以诱导例如耐热性，溶剂耐受性，改变的细胞生长，胰岛素产生，分化和耐药性。

公开(公告)号：WO2010087594A9

公开(公告)日：2011-11-10

申请号：PCT/KR2010000315

申请日：2010-01-18

Applicant: KOREA RES INST OF BIOSCIENCE ,  PARK YOUNG WOO ,  JEON JAE WON ,  JUNG JOON-GOO ,  CHOI HYE IN ,  SOHN MYUNG-HO ,  KIM HO YOUN ,  CHO MI-LA ,  JANG YOUNG-SOON ,  MOON JI-HUN ,  PARK JI HYUN

Inventor： PARK YOUNG WOO ,  JEON JAE WON ,  JUNG JOON-GOO ,  CHOI HYE IN ,  SOHN MYUNG-HO ,  KIM HO YOUN ,  CHO MI-LA ,  JANG YOUNG-SOON ,  MOON JI-HUN ,  PARK JI HYUN

IPC: A61K39/395 ,  A61K31/7105 ,  A61P29/00 ,  A61P37/08 ,  G01N33/53

CPC classification number: A61K31/7105 ,  G01N33/6893 ,  G01N2333/70596

Abstract: The present invention relates to an anti-inflammatory composition using an antibody specifically binding to CD93 or a soluble fragment thereof, a method for diagnosing inflammatory diseases using an aptamer or an antibody specifically binding to CD93 or a soluble fragment thereof, and a kit for diagnosing inflammatory diseases.

Abstract translation: 本发明涉及使用特异性结合CD93的抗体或其可溶性片段的抗炎组合物，使用特异性结合CD93或其可溶性片段的适体或抗体诊断炎性疾病的方法，以及用于诊断的试剂盒 炎性疾病。

公开(公告)号：WO2010044506A3

公开(公告)日：2010-07-15

申请号：PCT/KR2008006614

申请日：2008-11-10

Applicant: KOREA RES INST OF BIOSCIENCE ,  PARK YOUNG WOO ,  CHOI SO-YOUNG ,  JANG YOUNG-SOON ,  PARK JI HYUN ,  SONG EUN-JUNG ,  YU JUNG ,  SOHN MYUNG-HO ,  JEON JAE WON ,  JUNG JOON-GOO ,  KIM SUNGSUB ,  JANG MYEOUNG HEE

Inventor： PARK YOUNG WOO ,  CHOI SO-YOUNG ,  JANG YOUNG-SOON ,  PARK JI HYUN ,  SONG EUN-JUNG ,  YU JUNG ,  SOHN MYUNG-HO ,  JEON JAE WON ,  JUNG JOON-GOO ,  KIM SUNGSUB ,  JANG MYEOUNG HEE

IPC: C07K16/18

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00 ,  C12N9/6424

Abstract: The present invention relates to a transmembrane protease, serine (TMPRSS4) -specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to TMPRSS4. The TMPRSS4- specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.

Abstract translation: 本发明涉及跨膜蛋白酶，丝氨酸（TMPRSS4） - 特异性人抗体，更具体地涉及包含衍生自特异性结合TMPRSS4的人抗体的互补决定区（CDR）和构架区（FR）的人抗体。 在本发明的各种癌细胞中表达的TMPRSS4特异性人抗体可用于诊断癌症，疾病分类，可视化，治疗和预后评估。

公开(公告)号：WO2007139260A1

公开(公告)日：2007-12-06

申请号：PCT/KR2006/004702

申请日：2006-11-10

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  PARK, Young Woo ,  KIM, Semi ,  JO, Kiwon ,  PARK, Ji Hyun ,  JUNG, Heekyung ,  LEE, Kwang Pyo ,  PARK, So Jeong ,  JANG, Young-soon ,  CHOI, So-Young ,  JUNG, Joon-Goo ,  HONG, Hyo Jeong ,  YOON, Jeong Ho ,  PARK, Jong-Ho

Inventor： PARK, Young Woo ,  KIM, Semi ,  JO, Kiwon ,  PARK, Ji Hyun ,  JUNG, Heekyung ,  LEE, Kwang Pyo ,  PARK, So Jeong ,  JANG, Young-soon ,  CHOI, So-Young ,  JUNG, Joon-Goo ,  HONG, Hyo Jeong ,  YOON, Jeong Ho ,  PARK, Jong-Ho

IPC: A61K31/7084 ,  A61P35/00

CPC classification number: A61K31/7084 ,  C12N15/1137 ,  C12N2310/14

Abstract: The present invention relates to an anticancer agent containing a TMPRSS4 (transmembrane protease, serine 4) inhibitor as an effective ingredient, more precisely an anticancer agent containing an inhibitor of TMPRSS4 activity as an effective ingredient. The anticancer agent of the present invention can be used effectively for the treatment of cancer by inhibiting TMPRSS4 expression in cancer cells and thereby inhibiting cancer cell invasion and cancer cell growth.

Abstract translation: 本发明涉及含有TMPRSS4（跨膜蛋白酶，丝氨酸4）抑制剂作为有效成分的抗癌剂，更准确地说，涉及含有TMPRSS4活性抑制剂作为有效成分的抗癌剂。 本发明的抗癌剂可以通过抑制癌细胞中的TMPRSS4表达，从而抑制癌细胞侵袭和癌细胞生长而有效地用于治疗癌症。